Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients

Samuel Golpanian, Jill El-Khorazaty, Adam Mendizabal, Darcy L. DiFede, Viky Y. Suncion, Vasileios Karantalis, Joel Fishman, Eduard Ghersin, Wayne E Balkan, Joshua Hare

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: The role of patient age in the efficacy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial. Objectives: This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even in older subjects. Methods: Patients with ICM who received MSCs via transendocardial stem cell injection (TESI) as part of the TAC-HFT (Transendocardial Autologous Cells in Ischemic Heart Failure) (n = 19) and POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) (n = 30) clinical trials were divided into 2 age groups: younger than 60 and 60 years of age and older. Functional capacity was measured by 6-min walk distance (6MWD) and quality of life using the Minnesota Living With Heart Failure Questionnaire (MLHFQ) score, measured at baseline, 6 months, and 1 year post-TESI. Various cardiac imaging parameters, including absolute scar size, were compared at baseline and 1 year post-TESI. Results: The mean 6MWD was similar at baseline and increased at 1 year post-TESI in both groups: 48.5 ± 14.6 m (p = 0.001) for the younger and 35.9 ± 18.3 m (p = 0.038) for the older participants (p = NS between groups). The older group exhibited a significant reduction in MLHFQ score (-7.04 ± 3.54; p = 0.022), whereas the younger than 60 age group had a borderline significant reduction (-11.22 ± 5.24; p = 0.058) from baseline (p = NS between groups). Although there were significant reductions in absolute scar size from baseline to 1 year post-TESI, the effect did not differ by age. Conclusions: MSC therapy with TESI in ICM patients improves 6MWD and MLHFQ score and reduces myocardial infarction size. Importantly, older individuals did not have an impaired response to MSC therapy.

Original languageEnglish
Pages (from-to)125-132
Number of pages8
JournalJournal of the American College of Cardiology
Volume65
Issue number2
DOIs
StatePublished - 2015

Fingerprint

Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Cardiomyopathies
Stem Cells
Injections
Heart Failure
Cicatrix
Age Groups
Therapeutic Uses
Myocardial Infarction
Quality of Life
Clinical Trials
Surveys and Questionnaires

Keywords

  • Heart failure
  • Infarct size
  • Ischemic heart disease

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. / Golpanian, Samuel; El-Khorazaty, Jill; Mendizabal, Adam; DiFede, Darcy L.; Suncion, Viky Y.; Karantalis, Vasileios; Fishman, Joel; Ghersin, Eduard; Balkan, Wayne E; Hare, Joshua.

In: Journal of the American College of Cardiology, Vol. 65, No. 2, 2015, p. 125-132.

Research output: Contribution to journalArticle

Golpanian, Samuel ; El-Khorazaty, Jill ; Mendizabal, Adam ; DiFede, Darcy L. ; Suncion, Viky Y. ; Karantalis, Vasileios ; Fishman, Joel ; Ghersin, Eduard ; Balkan, Wayne E ; Hare, Joshua. / Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients. In: Journal of the American College of Cardiology. 2015 ; Vol. 65, No. 2. pp. 125-132.
@article{8d944d977cf944509654d3c3e7a69c20,
title = "Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients",
abstract = "Background: The role of patient age in the efficacy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial. Objectives: This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even in older subjects. Methods: Patients with ICM who received MSCs via transendocardial stem cell injection (TESI) as part of the TAC-HFT (Transendocardial Autologous Cells in Ischemic Heart Failure) (n = 19) and POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) (n = 30) clinical trials were divided into 2 age groups: younger than 60 and 60 years of age and older. Functional capacity was measured by 6-min walk distance (6MWD) and quality of life using the Minnesota Living With Heart Failure Questionnaire (MLHFQ) score, measured at baseline, 6 months, and 1 year post-TESI. Various cardiac imaging parameters, including absolute scar size, were compared at baseline and 1 year post-TESI. Results: The mean 6MWD was similar at baseline and increased at 1 year post-TESI in both groups: 48.5 ± 14.6 m (p = 0.001) for the younger and 35.9 ± 18.3 m (p = 0.038) for the older participants (p = NS between groups). The older group exhibited a significant reduction in MLHFQ score (-7.04 ± 3.54; p = 0.022), whereas the younger than 60 age group had a borderline significant reduction (-11.22 ± 5.24; p = 0.058) from baseline (p = NS between groups). Although there were significant reductions in absolute scar size from baseline to 1 year post-TESI, the effect did not differ by age. Conclusions: MSC therapy with TESI in ICM patients improves 6MWD and MLHFQ score and reduces myocardial infarction size. Importantly, older individuals did not have an impaired response to MSC therapy.",
keywords = "Heart failure, Infarct size, Ischemic heart disease",
author = "Samuel Golpanian and Jill El-Khorazaty and Adam Mendizabal and DiFede, {Darcy L.} and Suncion, {Viky Y.} and Vasileios Karantalis and Joel Fishman and Eduard Ghersin and Balkan, {Wayne E} and Joshua Hare",
year = "2015",
doi = "10.1016/j.jacc.2014.10.040",
language = "English",
volume = "65",
pages = "125--132",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Effect of aging on human mesenchymal stem cell therapy in ischemic cardiomyopathy patients

AU - Golpanian, Samuel

AU - El-Khorazaty, Jill

AU - Mendizabal, Adam

AU - DiFede, Darcy L.

AU - Suncion, Viky Y.

AU - Karantalis, Vasileios

AU - Fishman, Joel

AU - Ghersin, Eduard

AU - Balkan, Wayne E

AU - Hare, Joshua

PY - 2015

Y1 - 2015

N2 - Background: The role of patient age in the efficacy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial. Objectives: This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even in older subjects. Methods: Patients with ICM who received MSCs via transendocardial stem cell injection (TESI) as part of the TAC-HFT (Transendocardial Autologous Cells in Ischemic Heart Failure) (n = 19) and POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) (n = 30) clinical trials were divided into 2 age groups: younger than 60 and 60 years of age and older. Functional capacity was measured by 6-min walk distance (6MWD) and quality of life using the Minnesota Living With Heart Failure Questionnaire (MLHFQ) score, measured at baseline, 6 months, and 1 year post-TESI. Various cardiac imaging parameters, including absolute scar size, were compared at baseline and 1 year post-TESI. Results: The mean 6MWD was similar at baseline and increased at 1 year post-TESI in both groups: 48.5 ± 14.6 m (p = 0.001) for the younger and 35.9 ± 18.3 m (p = 0.038) for the older participants (p = NS between groups). The older group exhibited a significant reduction in MLHFQ score (-7.04 ± 3.54; p = 0.022), whereas the younger than 60 age group had a borderline significant reduction (-11.22 ± 5.24; p = 0.058) from baseline (p = NS between groups). Although there were significant reductions in absolute scar size from baseline to 1 year post-TESI, the effect did not differ by age. Conclusions: MSC therapy with TESI in ICM patients improves 6MWD and MLHFQ score and reduces myocardial infarction size. Importantly, older individuals did not have an impaired response to MSC therapy.

AB - Background: The role of patient age in the efficacy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial. Objectives: This study sought to determine whether the therapeutic effect of culture-expanded MSCs persists, even in older subjects. Methods: Patients with ICM who received MSCs via transendocardial stem cell injection (TESI) as part of the TAC-HFT (Transendocardial Autologous Cells in Ischemic Heart Failure) (n = 19) and POSEIDON (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis) (n = 30) clinical trials were divided into 2 age groups: younger than 60 and 60 years of age and older. Functional capacity was measured by 6-min walk distance (6MWD) and quality of life using the Minnesota Living With Heart Failure Questionnaire (MLHFQ) score, measured at baseline, 6 months, and 1 year post-TESI. Various cardiac imaging parameters, including absolute scar size, were compared at baseline and 1 year post-TESI. Results: The mean 6MWD was similar at baseline and increased at 1 year post-TESI in both groups: 48.5 ± 14.6 m (p = 0.001) for the younger and 35.9 ± 18.3 m (p = 0.038) for the older participants (p = NS between groups). The older group exhibited a significant reduction in MLHFQ score (-7.04 ± 3.54; p = 0.022), whereas the younger than 60 age group had a borderline significant reduction (-11.22 ± 5.24; p = 0.058) from baseline (p = NS between groups). Although there were significant reductions in absolute scar size from baseline to 1 year post-TESI, the effect did not differ by age. Conclusions: MSC therapy with TESI in ICM patients improves 6MWD and MLHFQ score and reduces myocardial infarction size. Importantly, older individuals did not have an impaired response to MSC therapy.

KW - Heart failure

KW - Infarct size

KW - Ischemic heart disease

UR - http://www.scopus.com/inward/record.url?scp=84922611540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922611540&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2014.10.040

DO - 10.1016/j.jacc.2014.10.040

M3 - Article

C2 - 25593053

AN - SCOPUS:84922611540

VL - 65

SP - 125

EP - 132

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -